Allostery is central to the regulation of many cellular processes. This ubiquitous mechanism refers to the control of protein behavior at a distance, with a change at one site (the allosteric site) affecting the function at a second. The functional coupling between these two sites is often mediated through structural rearrangements[@R1]. Well-characterized examples include the cooperative binding of oxygen to hemoglobin, whereby ligand binding at the allosteric site alters protein function through changes in quaternary structure (for review see[@R2]--[@R4]). Although conformational changes induced by allosteric effectors can frequently be detected, understanding *how* these structural alterations translate into changes in function is typically more challenging. This is because defining an allosteric signaling pathway requires the identification of specific amino acids that couple changes in structure or dynamics to changes in function.

The regulation of the *Clostridium difficile* glucosylating toxin cysteine protease domain (CPD) by the small molecule inositol hexakisphosphate (InsP~6~) is an ideal system for studying allosteric signaling pathways[@R5]--[@R8]. *C. difficile* CPDs belong to a conserved family of autocatalytic proteases within bacterial toxins that are allosterically activated by InsP~6~, a metabolite found abundantly in the eukaryotic cytosol[@R6],[@R9]. These clan CD protease members cleave exclusively on the C-terminal side of a leucine residue to liberate toxin effectors from receptor binding domains and other effectors[@R7],[@R10]--[@R13]. InsP~6~ activates bacterial CPDs by binding to a basic cleft that is distinct from the active site. This binding event induces conformational changes that are presumably linked to protease activation[@R11],[@R14],[@R15]. More specifically, InsP~6~ has been proposed to induce rearrangement of a β-hairpin structure to permit formation of the substrate binding pocket and alignment of the catalytic residues[@R11],[@R14],[@R15].

*C. difficile* CPDs function to autocatalytically cleave the glucosylating toxins TcdA and TcdB at a single site to liberate a cytotoxic effector domain into target cells[@R12],[@R16]. This event occurs at the later stages of a multi-step intoxication process[@R17],[@R18]. Glucosylating toxins first enter cells using receptor-mediated endocytosis; during acidification of the endosome, they undergo a conformational change that mediates toxin translocation across the endosomal membrane. Exposure of the CPD to InsP~6~ in target cells activates the protease, resulting in autocatalytic cleavage. This autoprocessing event releases the glucosyltransferase domain from the endosome into the cytosol and presumably enhances glucosyltransferase binding to its Rho GTPase substrates at the plasma membrane[@R19]. Glucosylation of Rho GTPases inhibits their function, leading to cell rounding and ultimately cell death[@R17].

Notably, the glucosylating toxins of *C. difficile* are the primary virulence factors of this important and emergent nosocomial pathogen[@R20],[@R21], and TcdB alone is sufficient to cause disease[@R22]. Because *C. difficile* is naturally antibiotic resistant, there is great interest in developing therapeutics that target glucosylating toxin function[@R20],[@R21],[@R23]. A more thorough understanding of CPD-mediated regulation of these toxins would likely facilitate the design of such therapeutics, since CPD activity is necessary for optimal toxin function[@R7],[@R10]. Understanding how the *eukaryotic-specific* small molecule InsP~6~ activates the CPD would further provide mechanistic insight into how allostery integrates environmental signals to regulate protein function.

In this study, we examined the mechanism underlying the allosteric activation of *C. difficile* TcdB CPDs by InsP~6~. Using a combination of structural analyses and an activity-based probe specific for TcdB CPD, we show that, even in the absence of InsP~6~, TcdB CPD transiently samples the activated conformation. InsP~6~ binding shifts the conformational equilibrium of the enzyme to an active conformer that is further stabilized by reaction with a suicide substrate. Using mutational studies, we demonstrate that adoption of this activated conformation depends upon an interconnected network of residues that functionally couple InsP~6~ binding to protease activation. These results therefore provide detailed mechanistic insight into a tightly controlled allosteric regulatory system used by a large family of bacterial pathogens. This information may facilitate the discovery of allosteric circuits in other systems and is likely to aid in the development of therapeutic agents that disrupt such networks.

Results {#S1}
=======

Measuring TcdB activation with an activity-based probe {#S2}
------------------------------------------------------

In order to dynamically monitor the InsP~6~-induced activation of *C. difficile* TcdB CPD, we sought to develop a reliable assay. Although autoprocessing can be used as a measure of InsP~6~-induced activation of TcdB CPD ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), this assay lacks the sensitivity needed to accurately measure the kinetics of this process. Fluorogenic substrate assays for the CPD also lack sensitivity because high substrate concentrations are needed to generate detectable activity[@R14]. In contrast, activity-based probe (ABP) labeling can be used to sensitively detect InsP~6~-induced CPD activation[@R24] ([Fig. 1a](#F1){ref-type="fig"}). ABPs are small molecules that exclusively label active enzyme[@R25],[@R26]. ABPs contain an electrophilic group that can only react with the active site nucleophile of an enzyme when the protein has assumed a catalytically competent conformation. We previously developed an ABP, AWP19, that specifically labels the CPD of full-length TcdB[@R24]. This probe consists of (i) an acyloxymethyl ketone (AOMK) reactive group that covalently modifies the catalytic Cys of clan CD proteases[@R27]--[@R29], (ii) a Ser-Leu peptide sequence that directs inhibitor binding to the CPD[@R24], and (iii) a Cy5 fluorophore tag that permits detection of the labeled enzyme. The Ser-Leu specificity element of AWP19 was identified by screening a small positional scanning library of inhibitors against TcdB CPD[@R24].

Titration of InsP~6~ against TcdB CPD in the presence of excess AWP19 resulted in a dose-dependent labeling of the protease in a manner dependent on the catalytic Cys ([Fig. 1b](#F1){ref-type="fig"}). This analysis yielded an activation constant (EC~50~) for TcdB CPD of 0.17 ± 0.06 μM ([Fig. 1c](#F1){ref-type="fig"}), the concentration of InsP~6~ at which probe labeling is half maximal. Notably, this value is identical to the EC~50~ determined using the standard autocleavage assay ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), validating AWP19 as a tool for measuring CPD activation.

Because AWP19 covalently labels the target only when the active site forms, it can be used to monitor the activation state of the CPD. We exploited this property to determine whether TcdB CPD could achieve an activated conformation independent of InsP~6~. Probe labeling with AWP19 indicated that approximately 10% of apo-CPD could be labeled in the absence of InsP~6~, whereas the catalytic Cys mutant was not labeled at all ([Fig. 1b](#F1){ref-type="fig"}). Furthermore, incubation of apo-CPD with probe for an extended period of time resulted in a time-dependent increase in labeling, with \~70% of the apo-enzyme being labeled after 16 hr ([Fig. 2a](#F2){ref-type="fig"}). Likewise, pre-incubation of apo-CPD with an unlabeled CPD-specific inhibitor (Ac-GSL-AOMK[@R24]) was sufficient to block probe labeling of the CPD in a time-dependent manner ([Fig. 2b](#F2){ref-type="fig"}), with \~70% of apo-CPD modified by the inhibitor after 16 hr treatment. The observed probe labeling of apo-CPD was not due to contamination with InsP~6~ during CPD purification from *E. coli* grown in InsP~6~-containing LB media, since apo-labeling was also observed when the CPD was purified from *E. coli* grown in minimal media (data not shown). These results demonstrate that apo-TcdB CPD can transiently sample the activated conformation.

We next used the probe to measure the effect of InsP~6~ binding on activation of the CPD. Whereas TcdB CPD labeling in the absence of InsP~6~ occurred very slowly (0.91 AU min^−1^, [Fig. 2c](#F2){ref-type="fig"} **inset**), InsP~6~ dramatically increased the rate of labeling in a dose-dependent manner (142 AU min^−1^ at 1 μM InsP~6~, [Fig. 2](#F2){ref-type="fig"}). Furthermore, we observed that \~20% of the TcdB~1--804~ autocleavage substrate undergoes CPD-dependent autoprocessing when produced in the InsP~6~-free environment of *E. coli* ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). These observations indicate that the TcdB CPD containing an N-terminal extension can also adopt the "ON"-state during expression in *E. coli*. Interestingly, this transient sampling of the "ON"-state by the apo-enzyme was specific to TcdB CPD, since expression of the related *V. cholerae* MARTX CPD in *E. coli* did not result in autoprocessing,[@R14],[@R30],[@R31] and *V. cholerae* CPD did not react with AWP19 in the absence of InsP~6~([Fig. 2](#F2){ref-type="fig"}, [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Together these results support the conclusion that apo-TcdB CPD can adopt an activated conformer in the absence of InsP~6~ and that InsP~6~ binding directly enhances the reactivity of the catalytic Cys by shifting the conformational equilibria of TcdB CPD to an activated form.

Small molecule binding and CPD conformational mobility {#S3}
------------------------------------------------------

In order for the AWP19 probe to label TcdB CPD, the protease must productively bind the peptide as it would a protein substrate[@R13],[@R24]. In related clan CD proteases, this inhibitor binding event has been shown to "lock" these enzymes in an active conformation[@R32],[@R33]. We questioned whether binding of a covalent inhibitor in the CPD active site might similarly induce retention of the enzyme in an active confirmation. Therefore we examined the effect of inhibitor modification on the conformational dynamics of TcdB CPD. To determine if the peptide backbone of the probe was required to constrain the CPD in the active form, we compared the effect of modifying TcdB CPD with the AOMK probe relative to the general alkylating agent N-ethylmaleimide (NEM). We used limited proteolysis as a read-out for conformational mobility, since this assay has previously been used to demonstrate that InsP~6~ stabilizes a protease-resistant conformation of *C. difficile* CPDs[@R5],[@R15] ([Fig. 3a](#F3){ref-type="fig"}, untreated). Covalent modification of apo-TcdB CPD by either inhibitor did not affect the limited proteolysis profile relative to untreated enzyme ([Fig. 3a](#F3){ref-type="fig"}, (−) panel), indicating that covalent modification alone is not sufficient to protect the enzyme from protease degradation. However, when InsP~6~ was added to these variants, AOMK treated but not NEM-modified CPD showed increased protection from protease degradation ([Fig. 3a](#F3){ref-type="fig"}**, (+) panel**). Covalent modification of TcdB CPD by either NEM or AOMK inhibitor blocked AWP19 labeling of these variants, indicating that the catalytic Cys of both variants were modified to similar extents ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). These results suggest that inhibitor modification in the context of substrate recognition is necessary to shift the equilibrium to a more stable conformer upon InsP~6~ addition.

Since the TcdB CPD used in these analyses had been covalently modified in its *apo*-form, we tested the effect of covalently modifying TcdB CPD in the *presence* of InsP~6~. Therefore we covalently modified TcdB CPD with either peptide AOMK or NEM in the presence of InsP~6~, re-purified the enzyme after these treatments, and subjected the TcdB CPD variants to complete trypsin digestion. As expected, only AOMK-modification of the CPD, and not NEM, modification markedly stabilized the enzyme ([Fig. 3b](#F3){ref-type="fig"}). Notably, InsP~6~ treatment increased the stability of the CPD even after re-purification of the enzyme, suggesting that InsP~6~ remains associated with TcdB CPD during this procedure ([Fig. 3b](#F3){ref-type="fig"}). These findings indicate that, while InsP~6~ binding to TcdB CPD can restrict its conformational dynamics, substrate binding by the protease further constrains the protease in the active form.

Another measure of TcdB CPD conformational mobility is its ability to release InsP~6~ after the re-purification procedure. We therefore created an assay that measures the activation of MARTX~Vc~ CPD as a result of transfer of InsP~6~ from TcdB CPD. Whereas no activation of the MARTX~Vc~ CPD was observed upon addition of apo-TcdB CPD, addition of either InsP~6~-treated TcdB CPD or NEM-bound, InsP~6~-treated TcdB CPD markedly increased its activity ([Fig. 3c](#F3){ref-type="fig"}). In contrast, addition of InsP~6~-treated TcdB CPD covalently modified by the AOMK peptide inhibitor resulted in only a minimal increase in MARTX~Vc~ CPD activity. Complete trypsin digestion of all InsP~6~-treated TcdB CPD variants, including NEM-bound and AOMK-bound, confirmed that similar levels of InsP~6~ were bound to each ([Fig. 3c](#F3){ref-type="fig"}). Together, these results suggest that substrate recognition by an InsP~6~-bound TcdB CPD restrains its conformational mobility such that it cannot release InsP~6~ without complete degradation of the protein. Thus, substrate recognition by TcdB CPD, in the context of binding to InsP~6~, would appear to "rigidify" the enzyme.

Effect of substrate binding on TcdB CPD structure {#S4}
-------------------------------------------------

To gain insight into the effect of substrate binding on TcdB CPD conformation in the presence of InsP~6~, we solved the crystal structure InsP~6~-bound TcdB CPD ([Fig. 4a](#F4){ref-type="fig"}) and compared it to the AOMK modified, InsP~6~-bound TcdB CPD[@R24]. Not surprisingly, the structure of TcdB CPD is highly similar to that of the recently reported structure of its close homolog (56% identity) TcdA CPD[@R15] (rmsd of 1.3Å). Most of the sequence differences between the two CPDs are found outside of regions involved in InsP~6~ binding and catalytic activity. The active site residues are completely conserved ([Fig. 4b](#F4){ref-type="fig"}), and residues in the InsP~6~ binding site are also conserved with the minor exception of two conservative basic substitutions (Lys577→Arg575, Lys754→Arg752) ([Fig. 4c](#F4){ref-type="fig"}). Core residues essential to the structure of the β-flap are also well conserved, including the π-cation interaction of Arg745 and Trp761 as well as Leu755, Glu753, and Asn747 (discussed below). While moderately divergent at the sequence level, the structural elements necessary for InsP~6~ binding and P1 leucine selectivity are tightly conserved in the TcdA and TcdB CPDs.

Comparison of the InsP~6~-bound TcdB CPD structure with that of InsP~6~-bound TcdB covalently modified by an Ac-GSL-AOMK peptide in the active site (PDB ID 35A8[@R24]) shows that the two structures are essentially superimposable (rsmd of 0.6 Å, [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). This observation implies that the active site forms upon InsP~6~ binding and furthermore that substrate binding does not make an induced fit. This is consistent with the previous observation that inhibitor binding does not alter the structure of InsP~6~-bound *V. cholerae* MARTX CPD[@R13]. These results suggest that the allosteric activation mechanism induced by InsP~6~ binding organizes the active site so that it can directly bind substrate.

Tryptophan fluorescence identifies an allosteric circuit {#S5}
--------------------------------------------------------

As in previous structures of bacterial CPDs, InsP~6~ binds to a positively charged cleft that is distal from the active site, and an antiparallel β-hairpin structure (termed the β-flap) appears to bridge the InsP~6~ and substrate binding pockets[@R11],[@R13]--[@R15]. This β-flap structure has been proposed to form upon InsP~6~ binding to the protease[@R6],[@R8], since residues on one side of the β-flap interact with InsP~6~, while residues on the other side form the substrate binding pocket ([Fig. 4](#F4){ref-type="fig"}). In MARTX~Vc~ CPD, residues within this region have been shown to respond to InsP~6~ binding[@R11]. Nevertheless, in the absence of an apo-structure, the precise conformational changes that occur upon InsP~6~ binding remain unknown.

To test whether InsP~6~-induced conformational rearrangements in the β-flap region could be detected in TcdB CPD, we developed an assay that monitors the mobility of a conserved β-flap tryptophan found in all bacterial CPDs.[@R6],[@R8] This β-flap Trp helps stabilize the substrate binding pocket of bacterial CPDs and affects the responsiveness of the enzyme to InsP~6~[@R11],[@R14],[@R15] Since the intrinsic fluorescence of Trp is strongly affected by its immediate environment[@R34], we assessed whether InsP~6~ binding induces changes in the intrinsic fluorescence of β-flap Trp761. Conveniently, Trp761 is the sole Trp in TcdB CPD; thus, all changes in tryptophan fluorescence emission can be attributed to changes in the local environment around this residue. Addition of InsP~6~ to TcdB CPD resulted in a dose-dependent increase in Trp fluorescence and concomitant decrease in the maximum wavelength of emission ([Fig. 5a](#F5){ref-type="fig"}), consistent with InsP~6~ binding to the CPD causing Trp761 to enter a more hydrophobic environment[@R34]. Thus, Trp fluorescence can be used to sensitively probe structural changes induced by InsP~6~ in the β-flap region.

In the InsP~6~-bound structures of TcdA[@R15] and TcdB CPD ([Fig. 4](#F4){ref-type="fig"}), Trp761 appears to be stabilized by a network of interactions that extends from the β-flap down to the InsP~6~ binding site. Trp761 forms a π-cation interaction with Arg745, while Arg745 is itself stabilized by an electrostatic interaction with Glu753. This latter residue also forms a hydrogen bond with Asn747 which, in turn, hydrogen bonds with the main chain amide of the InsP~6~-interacting residue, Arg751 ([Fig. 6](#F6){ref-type="fig"}). To determine the functional importance of these interactions on the InsP~6~-induced movement of Trp761, we examined the effect of mutating β-flap region residues on Trp fluorescence and CPD activity. Conservative mutation of Arg745 severely decreased Trp fluorescence but only slightly affected CPD activity (reduced by a factor of 3), while a stronger mutation (R745Q) completely abrogated Trp fluorescence and diminished CPD function by a factor of 25 ([Fig. 5b and c](#F5){ref-type="fig"}). Disruption of the salt bridge between Arg745 and Glu753 by mutating Glu753 to glutamine resulted in slight decreases in Trp fluorescence shift and CPD activity ([Fig. 5b and c](#F5){ref-type="fig"}), while a more severe mutation to asparagine abrogated the Trp fluorescence change altogether and reduced protease function by a factor of 20. Mutation of Asn747 to alanine similarly reduced the Trp fluorescence shift and decreased CPD activity by a factor of 24. Taken together, the results demonstrate that InsP~6~-induced changes in Trp fluorescence depend on a network of interactions between β-flap residues and that changes in Trp fluorescence directly correlate with levels of protease activity.

Similar effects on Trp fluorescence and protease activity were observed upon mutation of InsP~6~ interacting residues. Disruption of the electrostatic interactions between these residues and InsP~6~ both decreased Trp fluorescence and protease function ([Fig. 5b and d](#F5){ref-type="fig"}), even though Trp761 is far removed from these InsP~6~ binding residues. Our finding that Trp fluorescence shifts become saturated even at high InsP~6~ concentrations suggests that the range of InsP~6~-induced movement of Trp761 is diminished in the InsP~6~ binding site mutants relative to wild type. Thus, InsP~6~-induced movement of Trp761 appears to depend on a network of interactions extending from the InsP~6~ binding site through the β-flap region.

One possible mechanism for allosteric signaling to the active site involves a network of interactions that have a specific spatial and temporal order[@R2]. To explore this possibility, we disrupted the interconnectedness of this network by performing a salt-bridge swap. Residues in the Arg745--Glu753 salt bridge were exchanged to form the R745E E753R double mutant. Although this mutant retains the critical β-flap salt-bridge, it loses the π-cation interaction between Arg745 and Trp761 and the hydrogen bond between Asn747 and Glu753. Accordingly, the activity of the double mutant was decreased by a factor of 23 relative to wildtype TcdB CPD ([Fig. 4c](#F4){ref-type="fig"}). Collectively, these results identify a conduit of interconnected residues that communicate InsP~6~ binding to the active site.

Disulfide bond engineering the β-flap region {#S6}
--------------------------------------------

If in fact InsP~6~ binding directly induces formation of the β-flap, engineering a stabilization of this structure should improve the responsiveness of the CPD to InsP~6~. To this end, we introduced disulfide bonds designed to stabilize the β-flap structure and examined their effect on protease activity in response to InsP~6~ ([Fig. 6](#F6){ref-type="fig"}). This approach was possible due to the fact that wildtype CPD does not contain disulfide bridges. Remarkably, introduction of a disulfide bond between helix α4 and strand G~3~ of the β-flap (I762C E766C) produced a mutant that was more responsive to InsP~6~ than wild type ([Fig. 6](#F6){ref-type="fig"}). Reduction of this disulfide bond restored wildtype levels of activity to I762C E766C. A similar redox-responsive effect was observed when a disulfide bond was engineered in the upper β-flap region (L755C W761C; [Fig. 6](#F6){ref-type="fig"}). Furthermore, the L755C--W761C disulfide bond partially complemented the intrinsic defect of the W761C mutant ([Fig 6](#F6){ref-type="fig"}), indicating that stabilization of this region can partially overcome the loss of the Arg745--Trp761 interaction. However, disulfide mutants in the lower portion of the β-flap region had the opposite effect on protease activity ([Fig. 6](#F6){ref-type="fig"}). Replacement of the Arg745--Glu753 salt-bridge with a disulfide bond decreased CPD activity by a factor of \~80 relative to wildtype, whereas reduction of the disulfide bond restored activity close to wildtype levels ([Fig. 6](#F6){ref-type="fig"}). Formation of a disulfide bond across the InsP~6~ binding site (R751C E765C) also severely hampered CPD function, while addition of reductant largely reversed this defect ([Fig. 6](#F6){ref-type="fig"}). These studies suggest that restraining the mobility of the upper β-flap region enhances the responsiveness of the protease to InsP~6~, whereas restraining the mobility in the lower portion strongly diminishes its responsiveness to InsP~6~.

Discussion {#S7}
==========

Communication between functional sites, or allostery, is central to the regulation of many proteins. In most cases, however, the pathways through which the signal travels are poorly characterized[@R2]--[@R4]. Here we show that activation of a *C. difficile* cysteine protease domain by its allosteric ligand InsP~6~ depends upon formation of an orchestrated series of interactions within the β-flap. Our results suggest that the β-flap structure functionally and mechanically couples InsP~6~ binding to protease activation. Furthermore, our data indicate that, while InsP~6~ binding rapidly accelerates the formation of this activated conformation, the apo-enzyme can transiently, but detectably, sample the activated conformer.

Using systematic mutational and structural analyses, we identified a conserved set of interconnected residues in the β-flap region that directly communicate the InsP~6~ signal to the active site. In addition to the InsP~6~ interacting residues, which are necessary to sense the InsP~6~ signal ([Fig. 4c](#F4){ref-type="fig"}), this contiguous network involves hydrogen bonding between the InsP~6~ interacting residue Arg751 and β-flap residues Asn747 and Glu753; a salt-bridge between Glu753 and Arg745; and a π-cation interaction between Arg745 and Trp761. Disrupting the interconnectivity of these interactions reduces protease function, as evidenced by the defect caused by reversing the orientation of the Arg745--Glu753 salt-bridge ([Fig. 4c](#F4){ref-type="fig"}). The allosteric conduit appears to terminate at W761, since mutation of Leu755, a residue within van der Waals bond distance, had essentially no effect on CPD activity ([Fig. 6](#F6){ref-type="fig"}).

These mutational analyses have identified 12 out of 253 CPD residues that participate in InsP~6~ signaling ([Fig. 4c](#F4){ref-type="fig"}). While additional residues may be involved, perhaps in the substrate binding region, our data are consistent with the view that a small subset of conserved, physically connected residues propagate allosteric signals between distinct functional sites, as was recently shown for caspase−1[@R35] and FecA[@R36]. Our finding that \~5% of CPD residues participate in this long-range communication is also consistent with other bioinformatic analyses aimed at identifying allosteric circuits in other proteins using co-evolution[@R37].

The tryptophan fluorescence assays indicate that InsP~6~ signal transduction through this interconnected network of residues results in movement of the conserved β-flap residue W761 into a less solvent exposed environment ([Fig. 5](#F5){ref-type="fig"}). When coupled to activity assays, these biophysical analyses reveal that InsP~6~-induced structural changes correlate with enzyme activation ([Fig. 4c](#F4){ref-type="fig"}). The disulfide trapping studies further demonstrate that exogenous stabilization of the upper β-flap structure increases the responsiveness of the CPD to InsP~6~ in a redox-sensistive manner ([Fig. 6](#F6){ref-type="fig"}). Collectively, our results support a model in which the active conformation of TcdB CPD is stabilized by β-flap formation. More broadly, these types of analyses provide a framework for determining how structural alterations in an allosteric circuit couple to changes in protein function.

The emerging view of allostery proposes that allosteric effectors cause a redistribution in the relative populations of protein conformers rather than formation of a *de novo* conformer[@R2]--[@R4]. Thus, allosteric effectors perturb a *pre-existing* conformational equilibrium[@R2],[@R38]. The activity-based probe labeling experiments provide direct evidence in support of this theory. Because the probe is covalent and activity dependent, we were able to sensitively detect the transient adoption of an active conformer by the apo-enzyme over time ([Fig. 2](#F2){ref-type="fig"}). Our results indicate that probe labeling can be used to dynamically measure protein activation and to detect minor levels of conformers in a given population. We anticipate that activity-based probes[@R25] will be useful tools for biochemically dissecting allosteric mechanisms of regulation for a number of enzyme classes.

The adoption of the activated conformer of the CPD upon InsP~6~ binding directly correlated with a reduction in its conformational mobility[@R5] ([Fig. 3](#F3){ref-type="fig"}). Furthermore, substrate recognition of a peptide AOMK inhibitor in the presence of InsP~6~ more severely restrained the conformational dynamics of the CPD. Inhibitor binding and covalent modification of the InsP~6~-bound TcdB CPD resulted in a protein that was highly resistant to trypsin digestion and did not release its associated InsP~6~ in the transfer assay ([Fig. 3](#F3){ref-type="fig"}). Notably, a similar stabilization of the CPD was not observed when the active cysteine was modified with the general alkylating agent NEM. Thus, recognition of an optimal peptide substrate, rather than simple covalent inhibition alone, appears to be the primary factor in restraining CPD dynamics in the presence of InsP~6~ ([Fig. 3](#F3){ref-type="fig"}). We propose that, similar to the caspases[@R33], binding of the critical leucine acts as a "key" that "locks" the enzyme in a catalytically competent conformation. In contrast with the caspases, however, substrate binding does not induce conformational changes in TcdB CPD[@R13],[@R33],[@R39]. Rather, InsP~6~ binding appears to be the driving force behind the structural rearrangements that lead to protease activation, while substrate binding holds the activated conformer in place.

The observation that TcdB CPD remains conformationally flexible in the presence of InsP~6~ appears critical to its function as a protease. When the lower β-flap region was constrained by disulfide bond formation, protease activity was strongly diminished; in contrast, reduction of the disulfide bonds restored activity to levels similar to wild type ([Fig. 6](#F6){ref-type="fig"}). This latter observation indicates that, even though the double Cys mutations disrupted the allosteric circuit, physically linking Cys residues together was primarily responsible for severely reducing protease function. Interestingly, although the disulfide bond mutants constructed in this study were originally designed to increase the responsiveness of the CPD to InsP~6~, the majority of engineered disulfide linkages decreased TcdB CPD activity. Only the mutants whose disulfide bonds were engineered proximal to the β-flap (but outside the allosteric conduit defined by this study) resulted in greater responsiveness to InsP~6~ ([Fig. 6](#F6){ref-type="fig"}). For example, the I762C E766C mutant was predicted to stabilize the interaction between helix α4 and strand G~3~ of the β-flap, which in TcdA is linked by a salt bridge[@R15]. Covalent linkage of these residues, which are dispensable for protease activity, increased the sensitivity of TcdB CPD to InsP~6~. It is tempting to speculate that stabilizing the interaction between helix α4 and strand G~3~ promotes formation of the β-flap in the presence of InsP~6.~ Future structural analyses of the I762C E766C should allow this hypothesis to be tested.

A similar increase in InsP~6~ responsiveness was observed upon formation of a disulfide bond between W761C and the neighboring L755C residue relative to the reduced form. In contrast, covalent linkage of W761C to R745C effectively ablated enzyme activity ([Fig. 6](#F6){ref-type="fig"}). Given that Leu755 does not participate in the allosteric conduit ([Fig. 5b](#F5){ref-type="fig"}), but Arg745 is a key constituent, these results suggest that restraining protein dynamics within the allosteric circuit may impede signal propagation. Although we cannot discount the possibility that the engineered disulfide bonds alter the overall conformation of the β-flap in addition to "rigidifying" this region, this interpretation is consistent with the theory that conformational mobility underlies both allostery and catalysis[@R3],[@R40]--[@R42].

Based on these observations, restraining the conformational dynamics of TcdB CPD would appear to be an effective strategy for preventing the activation of *C. difficile* glucosylating toxin function by the CPD[@R43]. Inhibitors that prevent the allosteric transition[@R44] or that shift the conformational equilibrium to an inactive conformer[@R45],[@R46] could be more effective and suitable for therapeutic applications than peptidic compounds that target the active site. A clearer understanding of the activation mechanism might also facilitate the identification of cell-impermeable compounds that prematurely activate the protease and thus prevent the cytotoxic activity domain from entering cells. Such approaches will require studies of CPD dynamics in the context of full-length toxin before and after intoxication, since the holotoxin undergoes dramatic structural alterations during translocation[@R47],[@R48]. Indeed, a major challenge in understanding the allosteric mechanism that governs the autoproteolytic regulation of *C. difficile* toxin function will be defining how the conformational dynamics of the full-length toxin affects CPD dynamics and function. These studies may further inform our understanding of how InsP~6~ modulates protein behavior in a more general sense, since this small molecule directly binds to unrelated bacterial effector proteins[@R49] and eukaryotic enzymes involved in diverse processes[@R50]--[@R52].

Methods {#S8}
=======

Bacterial growth conditions and strain construction {#S9}
---------------------------------------------------

Bacterial strains were grown at 37°C in Luria-Bertrani (LB) broth. Antibiotics were used at 100 μg mL^−1^ carbenicillin for pET22b and 30 μg mL^−1^ kanamycin for pET28a vectors in *E. coli*. For details on strain construction, see the [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

TcdB CPD AWP19 probe labeling assay {#S10}
-----------------------------------

TcdB CPD (544--797 aa) was diluted into CPD buffer \[60 mM NaCl, 20 mM Tris pH 7.5, 250 mM sucrose\] to a final concentration of 1 μM. AWP19 was added to a final concentration of 10 μM (1:100 dilution of a DMSO stock) and then 50 μL aliquots were plated in a 96 well plate. InsP~6~ (Calbiochem) was added (1:100 dilution from stock in water) to the indicated concentrations in triplicate. AWP19 labeling was allowed to proceed for 1 hr at 37°C after which 30 μL of the reaction was transferred into 10 μL 4 × final sample buffer (FSB) in a second 96 well plate. The reaction was boiled for 3 min at 95°C and then 10 μL was resolved by SDS-PAGE (14% gel). The gel was scanned using a Typhoon imager and then Coomassie stained to ensure equal loading. For the redox sensitivity assays, the AWP19 probe labeling assay was performed as described except that the mastermix was divided into two, and DTT was added to a final concentration of 1 mM.

EC~50~ determination {#S11}
--------------------

Labeling reactions were quantified in triplicate using the program ImageJ (imagej.nih.gov/ij, National Institutes of Health). The absolute value for each InsP~6~ concentration was averaged and then corrected by subtracting the average value at 0 μM InsP~6~. The corrected values were plotted against InsP~6~ concentration, and the EC~50~ (the concentration of ligand that produced half-maximal labeling) was determined using the Michaelis-Menten function on KaleidaGraph.

Protein purification {#S12}
--------------------

For details see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Kinetics of AWP19 labeling {#S13}
--------------------------

For details see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Limited Chymotrypsin Proteolysis {#S14}
--------------------------------

TcdB CPD was diluted into 1.0 mL CPD buffer to a final concentration of 100 μM. The mastermix was divided into 3 tubes of 300 μL. Ac-GSL-AOMK was added to one tube to give a final concentration of 200 μM (20 mM stock in DMSO), while NEM was added to a second tube to give a final concentration of 200 μM (50 mM stock in DMSO). The third tube was left untreated. The samples were incubated for 16 hr at room temperature after which they were diluted with 900 μL of low imidazole lysis buffer. Fifty microlitres of Ni-NTA beads were added and incubated with nutation for 1 hr at room temperature; immobilized His~6~-tagged TcdB CPD was washed times and then eluted with two times with 100 μL high imidazole buffer. The TcdB CPD variants were then diluted to 18 μM in 10 mM Tris pH 7.5 buffer in a total volume of 300 μL. The mixture was split into two, and 1.75 μL of 10 mM InsP~6~ was added to one tube for a final concentration of 100 μM. Twenty-four microlitres of the mastermix was aliquoted into a 96 well plate and then chymotrypsin was added to the indicated concentration (1:25 dilution). Limited proteolysis was allowed to proceed for twelve minutes after which 7.5 μL of 4× FSB was added to the reactions. The samples were boiled for 3 min at 95°C and then 10 μL was resolved on a 14% SDS-PAGE gel and visualized by Coomassie staining.

Complete Trypsin digestion {#S15}
--------------------------

For details see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

InsP~6~ transfer assay {#S16}
----------------------

For details see [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

Crystallization and data collection {#S17}
-----------------------------------

For TcdB CPD bound to InsP~6~, initial crystal hits were observed in 0.1 M Tris HCl pH 8.0 and 30% (w/v) PEG2000 MME as the precipitant. Ultimately, diffraction quality crystals were grown using the sitting drop vapor-diffusion method by mixing 0.5 uL of protein with an equal volume of mother liquor and allowing the crystals to grow for 45 to 60 days. Crystals were cryoprotected in 45% (w/v) PEG2000 MME, and data was collected under cryo-cooled conditions at 100 K at the Advanced Light Source beamline 8.2.1 (Berkeley, CA). Diffraction data were processed using MOSFLM[@R53] and SCALA[@R54] from the CCP4 suite, and data processing statistics are listed in [Table 1](#T1){ref-type="table"}. Electron density of the structure is shown in [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}.

Structure determination and refinement {#S18}
--------------------------------------

Initial phases were obtained by molecular replacement with PHASER[@R55] using the structure of the inhibitor-TcdB complex (PDBID 35A8)[@R24] as a search model. The structure then underwent rounds of restrained refinement with PHENIX[@R56] followed by model adjustment with COOT[@R57], resulting in final R/Rfree values of 19.1 and 24.0%, respectively. Ramachandran analysis of structure geometry with Molprobity indicates 98.1% of residues reside in the most favourable regions, with none in disallowed regions[@R58]. Refinement statistics are listed in [Table 1](#T1){ref-type="table"}. Structural figures were prepared with Pymol[@R59] using chain A in all instances. The final model contains two copies of the TcdB CPD in the asymmetric unit, each bound to one molecule of InsP~6~ and a single calcium ion bridging the crystal interface between the two CPD molecules in the ASU.

Intrinsic tryptophan fluorescence assay {#S19}
---------------------------------------

TcdB CPD variants were diluted to 20 μM in 4.3 mL phosphate buffered saline (PBS) and divided into 600 μL aliquots. InsP~6~ was added to the indicated concentration (100-fold dilution) and then 190 μL aliquots were added in triplicate to a 96 well clear bottom black plate. The samples were excited at 295 nm, and the emission spectrum was measured at 1 nm increments from 325 nm to 375 nm. InsP~6~ was also added to PBS as the buffer control. The A280 of the plate was measured, and the average A280 for each prep was determined. The fluorescence values at each wavelength were averaged and the PBS background was subtracted. The resulting relative fluorescence unit (RFUs) was then divided by the average A280 value.

Supplementary Material {#SM}
======================
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**Accession codes**. Coordinates and structure factors have been deposited in the Protein Data Bank ([www.rcsb.org](http://www.rcsb.org)) under accession number 3PEE.

![Development of an activity-based probe assay for measuring TcdB CPD activity. (**a**) Structure of AWP19 activity-based probe. The residues in the peptide specificity element, the acyloxymethyl ketone (AOMK) electrophile, and Cy5 fluorophore are marked. (**b**) InsP~6~-induced labeling of TcdB CPD by AWP19. Recombinant TcdB CPD was mixed with AWP19 and incubated with the indicated concentration of InsP~6~. The labeling reactions were resolved by SDS-PAGE, and fluorescence was measured using a flatbed scanner, followed by visualization of total protein using Coomassie staining. No labeling was observed when the catalytic Cys is mutated to Ala. (**c**) Quantitation of EC~50~ (the concentration of InsP~6~ at which activity is half-maximal) for the AWP19 labeling assay.](nihms-254656-f0001){#F1}

![Detection of an active conformer in the apo-state using an activity-based probe. (**a**) Time-dependent labeling of apo-CPD by AWP19. TcdB CPD, in the absence of exogenous InsP~6~, was incubated with AWP19 for the indicated period of time, and reactions were resolved by SDS-PAGE. Probe labeling was visualized by fluorescent scanning. The percent labeling was compared relative to TcdB CPD incubated with InsP~6~ and AWP19 in parallel. (**b**) Pre-incubation of TcdB CPD with an AOMK inhibitor results in time-dependent inhibition of TcdB CPD activity. TcdB CPD was incubated with Ac-GSL-AOMK with or without InsP~6~ for the indicated times. Residual activity was measured by labeling the enzyme with AWP19 in the presence of InsP~6~. (**c**) Rate of AWP19 labeling of TcdB CPD in response to increasing InsP~6~ concentrations. The fluorescent signal (arbitrary units -- AU) was plotted against time. (**d**) Rate of AWP19 labeling measured in (c) plotted against InsP~6~ concentration. AWP19 labeling exhibited Michaelas-Menten like kinetics, allowing for the determination of a dissociation constant of 0.4 μM. This value is in agreement with the published *K~D~* determined using non-enzymatic methods[@R5].](nihms-254656-f0002){#F2}

![Effect of InsP~6~ and P1 Leu inhibitor modification on TcdB CPD conformational mobility. (**a**) Limited proteolysis profile of TcdB CPD variants with and without InsP~6~. TcdB CPD was either untreated, treated with N-ethylmaleimide (NEM), or treated with Ac-GSLAOMK for 16 hr. TcdB CPD variants were re-purified using the His~6~-tag and then subjected to limited proteolysis using chymotrypsin in the absence (−) or presence (+) of InsP~6~. Reactions were resolved by SDS-PAGE and visualized by Coomassie staining. (**b**) Trypsin digestion of TcdB CPD exposed to InsP~6~ in the presence or absence of covalent inhibitors. TcdB CPD was activated in the presence of InsP~6~ alone, or InsP~6~ and the indicated inhibitor. Treated CPDs were re-purified using gel filtration to remove inhibitor and excess InsP~6~. Untreated enzyme was also subjected to the same re-purification procedure. Re-purified TcdB CPD variants were digested with trypsin (0.2 mg mL^−1^), and aliquots were removed at the indicated timepoints and resolved by SDS-PAGE followed by Coomassie staining. (**c**) InsP~6~ transfer assay. Re-purified TcdB CPD variants from (b) prior to addition of trypsin (input) and after trypsin-digestion (Trypsin) were added to MARTX~Vc~ CPD and fluorogenic substrate cleavage was measured. InsP~6~ was also added directly to the fluorogenic cleavage assay to determine maximal protease activation of MARTX~Vc~ CPD. The percentages shown above bar graphs indicate the amount of exogenous InsP~6~ transferred to MARTX~Vc~ CPD relative to the total amount of InsP~6~ that could have been transferred assuming each TcdB CPD molecule carried a single InsP~6~ molecule through the re-purification procedure. Values are given as mean ± s.d. (n=3).](nihms-254656-f0003){#F3}

![Structure of TcdB CPD and comparison with TcdA CPD. (**a**) Overview of TcdB CPD structure. The first panel shows the InsP~6~ binding site, while the second panel shows the structure rotated 120° to reveal the active site. The catalytic Cys and His residues are shown as stick models, and the β-flap and bound InsP~6~ are labeled. The overall structure is colored from blue at the N-terminus to red at the C-terminus for orientation. (**b**) Overlay of the TcdB (green) and TcdA (light blue) CPD InsP~6~ binding sites. Sidechains within 3.5 Å of InsP~6~ are labeled (TcdB/TcdA) and shown as stick models. (**c**) Overlay of the TcdB (green) and TcdA (light blue) CPD active sites. The approximate S1 pocket that interacts with the P1 leucine is shaded. The catalytic Cys and His residues are shown as transparent spheres and labeled in red lettering; conserved residues near the active site are shown as stick models. Residue numbering is given as TcdA/TcdB.](nihms-254656-f0004){#F4}

![InsP~6~ binding induces movement of conserved Trp in β-flap region. (**a**) Effect of InsP~6~ on intrinsic tryptophan fluorescence of TcdB CPD. TcdB CPD was incubated with the indicated concentration of InsP~6~, and the fluorescence emission spectra measured after excitation at 295 nm. Fluorescence units (FU) refer to the relative fluorescence A280^−1^. (**b**) Close-up view of β-flap region. The β-flap ribbon structure is colored in purple, and residues required for CPD activity are shown in magenta as sticks. Select InsP~6~ interacting residues are shown as sticks and colored cyan. Residues dispensable for CPD activity are shown as sticks and colored purple. The EC~50~s for different point mutants were measured using the probe labeling assay and are expressed as mean ± s.d. (n=3). A lower EC~50~ indicates that the mutant is more sensitive to InsP~6~. Trp fluorescence emission of (**c**) wild type and β-flap mutants, and (**d**) InsP~6~ binding mutants at 340 nm was measured in the presence of increasing concentrations of InsP~6~.](nihms-254656-f0005){#F5}

![Effect of redox state on InsP~6~ responsiveness of engineered disulfide bond mutants in the β-flap. The β-flap is shown as a ribbon structure and colored purple. Residues mutated to Cys as pairs are shown as sticks and colored similarly. Catalytic residues are shown as sticks and colored red. EC~50~ for each mutant is shown in the presence (+DTT) or absence (S-S) of reductant. A lower EC~50~ indicates that the mutant is more sensitive to InsP~6~. Data are expressed as mean ± s.d. (n=3).](nihms-254656-f0006){#F6}

###### 

Data collection and refinement statistics

                          TcdB CPD in complex with InsP~6~
  ----------------------- -------------------------------------
  **Data collection**     
  Space group             C 2
  Cell dimensions         
   *a, b, c* (Å)          128.11, 45.71, 87.35
   α, β, γ (°)            90, 103.48, 90
  Resolution (Å)          1.0[\*](#TFN1){ref-type="table-fn"}
  *R* ~merge~             50−2.1 (2.22−2.1)
  *I* / σ*I*              8.4 (1.8)
  Completeness (%)        97.6 (91.8)
  Redundancy              3.2 (2.6)
  **Refinement**          
  Resolution (Å)          39.7−2.1
  No. reflections         26305/1337
  *R*~work~ / *R*~free~   19.2/24.0
  No. atoms               
   Protein                3854
   InsP~6~                72
   Calcium                1
   Water                  218
  *B*-factors             
   Protein                39.2
   InsP~6~                25.6
   Calcium                30.1
   Water                  40.0
  R.m.s. deviations       
   Bond lengths (Å)       0.008
   Bond angles (°)        1.308

Data was collected from a single crystal. Values in parentheses are for the highest-resolution shell.

[^1]: Current Address: Genentech, Inc, South San Francisco, California, USA

[^2]: Current Address: Pfizer, Inc, Sandwich, UK.
